Common stock, $0.001 par value per share
- Symbol
- LAB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Standard BioTools Inc.
LABNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 - Results of Operations and Financial Condition On January 8, 2026, Standard BioTools Inc. (the "Company") issued a press release, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.…
Press release in this filing
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue →Company context
Standard BioTools Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Standard BioTools’ established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Current securities
Historical securities (1)
Registered securities in this filing
Standard BioTools Inc. · 8-K · Filed 2026-01-08
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 - Results of Operations and Financial Condition
On January 8, 2026, Standard BioTools Inc. (the "Company") issued a press release, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company's financial results for the three months or fiscal year ended December 31, 2025 and remains subject to the completion of financial closing procedures and internal reviews.
Filed exhibits (1)
Exhibit 99.1 Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 million BOSTON, Mass., January 8, 2026 -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million. For the full year 2025, the Company expects combined company revenue of approximately $185 million and revenue from continued operations of approximately $85 million. "Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations,” said Michael Egholm, PhD, Chief Executive Officer of Standard BioTools. “Amid a shifting macro backdrop, the team remained focused - managing what we could control to drive the business forward.” Dr. Egholm added, “We conti…
Open exhibit ↗